North America Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Industry Trends Analysis Report By Type (Antacids, Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, and Pro-kinetic Agents), By Country and Growth Forecast, 2022 - 2028

North America Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Industry Trends Analysis Report By Type (Antacids, Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, and Pro-kinetic Agents), By Country and Growth Forecast, 2022 - 2028

The North America Gastroesophageal Reflux Disease Therapeutics Market would witness market growth of 1.5% CAGR during the forecast period (2022-2028).

A burning sensation behind the breastbone is a symptom of gastroesophageal reflux disease (GERD), characterized by the reflux of stomach contents into the mouth via the esophagus. The lower oesophageal sphincter and the digestive tract's suppleness are impacted by gastroesophageal reflux disease (GERD), a common digestive disorder. Dietary changes, lifestyle changes, and excessive consumption of fatty foods, coffee, alcohol, citrus fruits, and pepper bring on gastroesophageal reflux disease.

Gastroesophageal reflux disease, brought on by excessive acid production and finally results in ulcers, rips the stomach's lining apart. Regurgitation and dysphagia are two additional symptoms of gastroesophageal reflux disease. Common symptoms of abnormal reflux include coughing, sore throat, otitis media, chest pain, enamel erosion, or other dental symptoms.

Inadequate esophageal clearance of refluxate may increase the amount of time that refluxate is in touch with the distal esophageal mucosa, which increases the likelihood that symptoms will develop or that the epithelium may be harmed. The key events that clear the refluxate are primary (swallow-induced) and secondary (distension-induced) peristalses. Around 30% of GERD patients have esophageal motility abnormalities, with inefficient esophageal motility being the most common change.

The World Health Organization's (WHO) burden of disease studies places alcohol intake as the second-highest etiologic risk factor in high-income nations like Canada. According to statistics from 2002, the projected yearly cost of health care directly associated with alcohol use in Canada was $3.3 billion, while the overall direct and indirect cost was $14.6 billion. The significant illness burden caused by alcohol in Canada is anticipated to rise due to many important factors. In addition, young individuals are more likely to engage in high-risk drinking. Around 32% of Canadians had issues the previous year due to other people's drinking, and almost one in five drinks more than the limits suggested for low-risk drinking. The growing population who consumes alcohol will increase the cases of gastroesophageal reflux diseases and surge the market growth in the region.

The US market dominated the North America Gastroesophageal Reflux Disease Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,501.1 Million by 2028. The Canada market is poised to grow at a CAGR of 3.8% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 2.9% during (2022 - 2028).

Based on Type, the market is segmented into Antacids, Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, and Pro-kinetic Agents. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC, Eisai Co., Ltd., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Medigus Ltd., Sebela Pharmaceuticals, Phathom Pharmaceuticals, Inc., and Camber Pharmaceuticals, Inc. (Hetero Labs Limited).

Scope of the Study

Market Segments covered in the Report:

By Type

• Antacids
• Proton Pump Inhibitors (PPIs)
• H2 Receptor Blockers
• Pro-kinetic Agents

• US
• Canada
• Mexico
• Rest of North America

• AstraZeneca PLC
• Eisai Co., Ltd.
• GlaxoSmithKline PLC
• Takeda Pharmaceutical Company Limited
• Ironwood Pharmaceuticals, Inc.
• Johnson & Johnson
• Medigus Ltd.
• Sebela Pharmaceuticals
• Phathom Pharmaceuticals, Inc.
• Camber Pharmaceuticals, Inc. (Hetero Labs Limited)

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free